Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Merck Research Laboratories Direct Human Health R&D by Year
Merck Research Laboratories (MRL) Direct Human Health R&D ($B)
Merck Merck Research Laboratories Direct Human Health R&D: $10.80B in FY2025, up 6.9% from a year earlier.
Latest, FY2025
10.80
Period ended Dec 31, 2025
Change on a year earlier
+6.9%
10.10 in FY2024
History
2 years
Since FY2024
Sources
1
Form 10-K (mrk-20251231.htm, filed 2026-02-24)
Where the FY2025 figure comes from
“R&D expenses consist of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $10.8 billion in 2025 and $10.1 billion in 2024.”
Source: Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Reported in Form 10-K MD&A Research and Development.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Merck Research Laboratories (MRL) Direct Human Health R&D ($B) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.80 | +6.9% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 10.10 | – | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
Cite this data
StockData. (2026). Merck Merck Research Laboratories Direct Human Health R&D, annual FY2024–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rd-mrl-direct-b
See every metric in the Merck KPI table. Data updated Oct 26, 2026.